Compare Citius Pharmaceuticals Inc (CTXR) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Dollar General Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Dollar General Corp. trades at $123.9 (market cap $27.42B). The key difference: Dollar General Corp. is far larger — about 2013.2× Citius Pharmaceuticals Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Dollar General Corp. for 59 Days on average.
| CTXR | DG | |
|---|---|---|
Market Cap | $13.62M | $27.42B |
Volume | 132,438 | 2,291,517 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $156.26 |
52-Week Low | $0.48 | $95.94 |
Typical Hold Time | 16 Days | 59 Days |
Enterprise Value | $3.79M | $41.60B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
DG trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong profitability with a 19.69% ROE and has beaten earnings estimates for the last three quarters. Recent news highlights margin benefits from tariff refunds and expansion of delivery services through Instacart. Cash flow from operations improved to $3.0 billion in 2025, supporting financial stability.
The outlook is positive with a consensus price target of $137.27, implying over 12% upside. Risks include competitive pressures and potential consumer spending weakness. Analyst sentiment is bullish with 55.77% buy ratings, but net income margin compression from 7.01% in 2022 to 2.77% in 2025 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
